Botulinum toxin in the management of spasticity in adults.
Botulinum toxin (BTX) is a powerful neurotoxin which blocks cholinergic transmission at the neuromuscular junction. Judiciously applied, it can reduce local muscle overactivity while maintaining the strength in other muscles. To date BTX has not been licensed for use in spasticity in the UK and the literature pertaining to clinical practice is still relatively scant. However, controlled trials have provided evidence of the effectiveness of BTX both in reducing spasticity itself and in achieving functional gain. The guidance given here to clinicians involved in the management of spasticity covers the types of patient suitable for treatment using BTX, the appropriate dosage, and the necessary follow-up procedures and documentation.
Turner-Stokes
Lynne
L
Regional Rehabilitation Unit, Northwick Park Hospital, Harrow, Middlesex.
Ward
Anthony
A
D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D009468:Neuromuscular Diseases / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins